204 related articles for article (PubMed ID: 32051301)
1. Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand.
Satirapoj B; Pratipanawatr T; Ongphiphadhanakul B; Suwanwalaikorn S; Benjasuratwong Y; Nitiyanant W
BMJ Open; 2020 Feb; 10(2):e031612. PubMed ID: 32051301
[TBL] [Abstract][Full Text] [Related]
2. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.
Lund A; Knop FK
Curr Med Res Opin; 2012 May; 28(5):731-6. PubMed ID: 22462528
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
4. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.
Alvarez Guisasola F; Tofé Povedano S; Krishnarajah G; Lyu R; Mavros P; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():25-32. PubMed ID: 18435671
[TBL] [Abstract][Full Text] [Related]
6. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
[TBL] [Abstract][Full Text] [Related]
7. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.
Kosachunhanun N; Benjasuratwong Y; Mongkolsomlit S; Rawdaree P; Plengvidhya N; Leelawatana R; Bunnag P; Pratipanawatr T; Krittiyawong S; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Ngarmukos C; Komoltri C
J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S66-71. PubMed ID: 17715836
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
[TBL] [Abstract][Full Text] [Related]
9. Impact of Hypoglycemia on Health-Related Quality of Life among Type 2 Diabetes: A Cross-Sectional Study in Thailand.
Pratipanawatr T; Satirapoj B; Ongphiphadhanakul B; Suwanwalaikorn S; Nitiyanant W
J Diabetes Res; 2019; 2019():5903820. PubMed ID: 31772942
[TBL] [Abstract][Full Text] [Related]
10. The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece.
Pagkalos E; Thanopoulou A; Sampanis C; Bousboulas S; Melidonis A; Tentolouris N; Alexandrides T; Migdalis I; Karamousouli E; Papanas N
Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):53-60. PubMed ID: 28704857
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.
Jermendy G; ; Erdesz D; Nagy L; Yin D; Phatak H; Karve S; Engel S; Balkrishnan R
Health Qual Life Outcomes; 2008 Oct; 6():88. PubMed ID: 18976457
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
[TBL] [Abstract][Full Text] [Related]
15. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
Int J Clin Pract; 2013 Oct; 67(10):1005-14. PubMed ID: 23981060
[TBL] [Abstract][Full Text] [Related]
17. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
[TBL] [Abstract][Full Text] [Related]
18. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
19. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
[TBL] [Abstract][Full Text] [Related]
20. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]